Core Viewpoint - Bicara Therapeutics provided an update on their clinical data related to head and neck cancer during a conference call, coinciding with a presentation at the 2026 Multidisciplinary Head and Neck Cancer Symposium [2]. Group 1: Company Overview - Bicara Therapeutics is focused on developing innovative therapies for cancer treatment, specifically in the area of head and neck cancer [2]. - The company’s Chief Corporate Affairs Officer, Jenna Cohen, led the conference call to discuss recent developments and data [2]. Group 2: Clinical Data Presentation - The data presented by Dr. Dan Zandberg from the UPMC Hillman Cancer Center was highlighted in a press release issued by the company [2]. - The press release and accompanying slides are available on the company's website for investors [2].
Bicara Therapeutics Inc. (BCAX) Discusses Ficerafusp Alfa Clinical Data and Less Frequent Dosing in First-Line HPV-Negative Head and Neck Squamous Cell Carcinoma Transcript